Navigation Links
Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
Date:1/31/2012

DURHAM, N.C., Jan. 31, 2012 /PRNewswire/ -- Argos Therapeutics Inc., today announced that it presented a high resolution immune monitoring analysis of AGS-003-006, a Phase 2 study of its Arcelis™ immunotherapy, AGS-003, in combination with sunitinib in patients with advanced renal cell carcinoma (RCC). The results showed a statistically significant correlation between anti-tumor memory T cell responses and overall survival. AGS-003 in combination with sunitinib overcame the immuno-suppressive environment of RCC and induced a tumor-specific multi-functional memory CTL response. The results were presented orally at the Global Technology Community's (GTC) 4th Immunotherapeutics and Immunomonitoring Conference in San Diego.

"We believe that the high resolution immune monitoring analysis of the Phase 2 study of AGS-003 and sunitinib represents the first time that pattern recognition algorithms originally developed for gene microarray datasets have been applied to an immunologic dataset to identify immune correlates to clinical outcome," said Charles Nicolette, Ph.D., Argos' chief scientific officer and vice president of research and development. "The multiparametric flow cytometry data from the study that we analyzed demonstrated that the combination of AGS-003 and sunitinib induced tumor-specific multi-functional memory CTL that were statistically significant correlates to overall survival in the study, thereby supporting the intended mechanism of action of AGS-003."

AGS-003-006 was an open label Phase 2 trial of AGS-003 in combination with sunitinib in patients with newly diagnosed, unfavorable-risk, metastatic clear cell RCC. AGS-003 was designed to stimulate the proliferation and multi-functionality of CTLs targeted directly to the autologous RCC tumor antigens.  In analyzing the data from the trial we sought to detect immune correlates by using multi-parametric flow cytometry to identify 16 unique RCC antigen reactive CTL subsets ba
'/>"/>

SOURCE Argos Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
2. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
3. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
5. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
7. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Silence Therapeutics Additional Listing
10. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
11. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... hold a conference call and live audio webcast on ... discuss its third quarter 2014 financial results. ... by dialing (888) 347-1165 for domestic callers or (412) ... webcast live under the investor relations section of the ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... , 3Q09 Corporate Highlights: ... Astellas Pharma Europe Ltd. Made significant progress in ... Sales; Senior Director, Marketing; and Director, Commercial Operations Appointed ... chairman , Upcoming 2009 Milestones: ...
... . . . Fuel economy ratings for ... the www.fueleconomy.gov web site, which Oak Ridge National ... and the U.S. Environmental Protection Agency. Nine of the top ... electrics, led by the Toyota Prius (51 MPG city; 48 ...
... 5 ThermoGenesis Corp. (Nasdaq: KOOL ), a leading ... cells, today reported results for the first quarter of fiscal ... Company reported revenues of $5.2 million, a 15 percent increase ... year ago. The Company said the key contributors to the ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
(Date:10/30/2014)... professor has received a $1.04 million grant from ... tissue and reduce osteoarthritis using a patient,s own ... made of biodegradable polymers., Liping Tang, a bioengineering ... said the research is primarily focused on helping ... "We,ve found that if we inject microscaffolding that ...
(Date:10/30/2014)... available in German . ... our fellow humans to behave socially? This is one ... game theory. Previous studies assumed that it is almost ... from the Max Planck Institute for Evolutionary Biology have ... influence on the cooperative behaviour of others. However, the ...
(Date:10/30/2014)... Bacteria in the gastrointestinal tract fulfill many vital ... same bacteria can induce strong inflammatory responses by ... and enter the bloodstream. , Although acute inflammation ... chronic or systemic inflammation is linked to numerous ... involvement of inflammatory processes in the development of ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2
... population in Canada, but the statistics are even more ... a study published recently in the American Journal of ... to 65 per cent of Cree preschoolers in northern ... Willows, a community nutritionist at the University of Alberta, ...
... potential has so far gone largely untapped. But new research ... shows that adult stem cells taken from skin can be ... The findings are reported in the Feb. 12 online edition ... Embryonic stem cells have received the most press for their ...
... the April 15th issue of Genes & Development, Dr. ... the minimal DNA structure sufficient to activate the ATR-mediated ... about these results," says Dr. Cimprich. "The ability to ... activating structure in an experimental system will enable us ...
Cached Biology News:Scientists clone mice from adult skin stem cells 2Scientists clone mice from adult skin stem cells 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... Cytokeratin TYPE II Reacts with most ... epidermal cell keratin of 86 and 58kD ... Broad keratin reactivity is found on human ... Immunogen: Human epidermal cells ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
Biology Products: